Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma Corporation has announced the date for the release of their second quarter 2024 financial results and a corporate update, scheduled for August 1, 2024. The company specializes in developing treatments for chronic hepatitis B and will share updates via press release and a webcasted conference call.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
